NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
PMN
ProMIS Neurosciences, Inc.
There isn't enough reported data to score PMN yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
PMN Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Unavailable | |
| Unavailable |
PMN's revenue is currently strong, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
PMN PE Valuation
PMN has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
PMN Forward outlook
There aren't enough analyst estimates for PMN to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over PMN on earnings quality, reporting a profit while its opponent remains loss making.
PMN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$8.89 | +$9.81 |
| Q2 2026 | -$14.00 | -$9.05 |
| Q1 2026 | -$19.97 | -$19.02 |
| Q4 2025 | -$23.96 | -$23.51 |
| Q3 2023 | -$51.24 | -$7.24 |
| Q2 2023 | -$67.74 | -$40.43 |
| Q1 2023 | -$70.49 | -$51.86 |
| Q4 2022 | -$62.39 | -$22.63 |
PMN is still losing money, but far less than before: $8.89 per share over the past year, against $70.49 at its worst in early 2023.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
PMN Quarterly Revenue
PMN's revenue is growing: $3,612 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2022 | -95778% | N/A |
| Q4 2021 | -123523% | N/A |
| Q3 2021 | -40368% | N/A |
| Q2 2020 | 105445% | N/A |
| Q4 2019 | -193205% | N/A |
PMN's operating margin was −95778% last quarter, up 97427 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over PMN on cash generation, producing positive trailing cash flow while its opponent burns cash.
PMN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.4M | +$678.5K |
| Q2 2026 | -$10.4M | -$6.5M |
| Q1 2026 | -$12.4M | -$7.5M |
| Q4 2025 | -$9.3M | -$566.9K |
| Q3 2025 | -$10.1M | -$3.4M |
| Q2 2025 | -$3.9M | -$2.3M |
| Q1 2025 | -$4.9M | +$5.4M |
| Q4 2022 | -$4.6M | -$485.3K |
PMN has burned cash in almost every quarter: −$41M over the past year, against −$28M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over PMN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
PMN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +974 shares |
| 1 year | +368% | +7.2M shares |
| 3 years | +2564% | +8.8M shares |
| 5 years | +4383% | +8.9M shares |
| Available history | +5146% | +9M shares |
PMN has 9M diluted shares, up 368% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
PMN Net Leverage
PMN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
PMN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.4 | Neutral |
| Stochastic | 5.5 | Oversold |
PMN's weekly RSI is 30 (neutral) and its Stochastic is 5 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
PMN PE vs Healthcare Sector
PMN has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over PMN on trend strength, trading above more of its moving averages.
PMN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.21 | 52% below |
| 20 week MA | $11.2 | 69% below |
| 50 week MA | $11.8 | 70% below |
| 100 week MA | $13.6 | 74% below |
| 200 week MA | $38.6 | 91% below |
PMN is in a downtrend: it's below all five of its weekly moving averages, and 91% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over PMN on returns for 2026, with the stronger performance.
PMN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $195.0 | $90.0 | -54% |
| 2021 | $90.0 | $165.0 | +83% |
| 2022 | $165.0 | $119.3 | -28% |
| 2023 | $119.3 | $28.8 | -76% |
| 2024 | $28.8 | $22.5 | -22% |
| 2025 | $22.5 | $7.66 | -66% |
| 2026 YTD | $7.66 | $3.48 | -55% |
PMN has finished four years in a row lower, and it's down 55% so far in 2026.